Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05393180 · ClinicalTrials.gov registry record · NA
CONVERGE Post-Approval Study (PAS)
A NA study of Chronic Atrial Fibrillation, sponsored by AtriCure.
- Active
- Registry status
- NA
- Development phase
- 53
- Enrollment target
- 13
- Study locations
NCT05393180: Active NA study of Chronic Atrial Fibrillation, sponsored by AtriCure.
NCT05393180 is a NA study of Chronic Atrial Fibrillation that is active but no longer recruiting, run by AtriCure. The registered enrollment target is 53 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05393180, a NA study of Chronic Atrial Fibrillation, is active but no longer recruiting, sponsored by AtriCure.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
- 13
- Study locations
Study Summary
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Primary Outcome
Primary Effectiveness Endpoint: The primary effectiveness endpoint is defined as the number of participants that exhibit freedom from AF/AT/AFL absent class I and III AADs except for a previously failed or intolerant class I or III AAD with no increase in dosage following the 90-day blanking period through the 12-months post procedure follow-up visit. The primary effectiveness endpoint will be evaluated based on the first 24 hours of the 7-days Holter monitoring. Participants will be consider
Conditions Studied
Interventions
- DEVICE Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF
Study Locations (13)
Florida
- Baycare Health Systems - Clearwater
- Orlando Health - Orlando
Georgia
- Emory Saint Joseph Hopsital - Atlanta
- Wellstar Health System - Marietta
California
- Sutter Bay Hospitals - San Francisco
Connecticut
- Hartford Hospital - Hartford
Kentucky
- Norton Heart & Vascular Institute - Louisville
Maryland
- MedStar Union Memorial Hospital - Baltimore
Massachusetts
- Southcoast Hospitals Group - New Bedford
New Jersey
- AtlantiCare Medical Center - Atlantic City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2022-04-13 |
| Est. Completion | 2029-01-01 |
| Phase | NA |
What the registry record for NCT05393180 still lists
NCT05393180 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Chronic Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF is the first listed.
NCT05393180 lists 13 locations in 11 states (Florida, Georgia, California).
Frequently Asked Questions
What is clinical trial NCT05393180 about?
NCT05393180 is a clinical study titled "CONVERGE Post-Approval Study (PAS)". The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillati...
What is the current status of trial NCT05393180?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 53 participants. The study started on 2022-04-13. Estimated completion is 2029-01-01.
What conditions does trial NCT05393180 study?
This clinical trial studies the following conditions: Chronic Atrial Fibrillation.
What interventions are being tested in trial NCT05393180?
The interventions under investigation include: Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF (DEVICE).
Who is sponsoring clinical trial NCT05393180?
This trial is sponsored by AtriCure, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05393180 being conducted?
This trial has 13 study locations across California, Connecticut, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05393180's enrollment target sits among peer trials
53 1271st of 2000 higher than 729 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI